製品番号: HY-W026930

Benzanthrone

カスタマーレビュー

Based on 1 Customer Validation

Benzanthrone is an immunotoxic, pro-inflammatory Photosensitizer. Benzanthrone upregulates iNOS, COX-2 and inflammatory cytokines; activates ERK1/2, p38, JNK, AP-1 and NF-κB; inhibits Nrf2; and induces oxidative stress and DNA damage. Upon radiation exposure, Benzanthrone generates singlet oxygen and superoxide anion radicals, induces photohemolysis and lipid peroxidation, and alters the levels of skin xenobiotic enzymes. Benzanthrone exhibits differential genotoxicity in different cell lines. Benzanthrone possesses skin tumor-initiating and promoting activities. Benzanthrone can be used in skin tumor-related studies.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.69%
CAS 番号: 82-05-3
分子式: C₁₇H₁₀O
分子量:230.26

保管条件:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Benzanthrone 構造式

CAS 番号: 82-05-3

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

iNOS

COX-2

ERK1

ERK2

NO Synthase アイソフォーム固有の製品をすべて表示 :

COX アイソフォーム固有の製品をすべて表示 :

ERK アイソフォーム固有の製品をすべて表示 :

p38 MAPK アイソフォーム固有の製品をすべて表示 :

JNK アイソフォーム固有の製品をすべて表示 :

AP-1 アイソフォーム固有の製品をすべて表示 :

NF-κB アイソフォーム固有の製品をすべて表示 :

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	Inhibition	127.309 % Compound: BENZANTHRONE	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	[PMID: 23571415]
CHO	Inhibition	69.7396 % Compound: BENZANTHRONE	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	[PMID: 23571415]

体外実験

Benzanthrone (10 μM; 18 h) does not induce detectable DNA adduct formation in human A549 or HepG2 cells^[2].
Benzanthrone (10 μM; 18 h) induces significant genotoxic lesions (DNA strand breaks/alkali-labile sites) in human A549 cells, but not in human HepG2 cells^[2].
Benzanthrone (10 μM; 18 h) induces significant oxidative DNA damage in human A549 and HepG2 cells, with greater damage observed in A549 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Benzanthrone (i.p.; daily; for 1 week, at doses of 3.25-15 mg/kg) induces dose-dependent immunotoxicity and inflammatory responses in female Balb/c mice via oxidative stress, DNA damage, activation of the MAPK pathway, and upregulation of inflammatory cytokines and markers, with the most significant effects observed at the 15 mg/kg dose^[1].
Benzanthrone (0.3%; topical administration; once daily for 3 consecutive days, sensitization; 0.15%; topical administration; single dose, challenge) induces significant delayed-type hypersensitivity in female Balb/c mice, characterized by ear swelling, increased MPO activity, and inflammatory cell infiltration^[1].
Benzanthrone (0.5-2.0 × 10^-7 mol/cm²; percutaneous administration; single dose) acts as a potent skin photosensitizer in guinea pigs. After exposure to natural sunlight or simulated UVA radiation, the duration of its induced erythema, edema, pigmentation and skin toxicity increases in a dose-dependent manner^[4].
Topical administration of commercial Benzanthrone (150 nmol; twice weekly for 30 weeks) induces abnormal changes in xenobiotic-metabolizing enzymes in mouse skin^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c (female, 6-8 weeks old, 18-20 g)^[1]
Dosage:

3.25 mg/kg; 7.5 mg/kg; 15 mg/kg
Administration:

i.p.; daily; 1 week
Result:

Caused dose-dependent inflammation at 7.5 mg/kg and 15 mg/kg.
Induced splenic hyperplasia with megakaryocyte infiltration, and lung alveolar septal thickening, edema, and focal hemorrhages at 15 mg/kg.
Showed no notable changes at 3.25 mg/kg.
Increased splenic MPO activity by 157% and lung MPO activity by 193% at 7.5 mg/kg.
Increased splenic MPO activity by 571% and lung MPO activity by 666% at 15 mg/kg.
Increased ROS generation (2-fold), lipid peroxidation (106%), and protein carbonyl content (25%); decreased GSH content (55%), SOD activity (24%), GST activity (37%), GR activity (34%), catalase activity (12%), and GPx activity (74%); reduced Nrf2 protein levels; and increased γ-H2AX protein levels (1.9-fold) in spleen at 7.5 mg/kg.
Increased ROS generation (2.9-fold), lipid peroxidation (450%), and protein carbonyl content (173%); decreased GSH content (73%), SOD activity (66%), GST activity (75%), GR activity (55%), catalase activity (29%), and GPx activity (85%); further reduced Nrf2 protein levels; and increased γ-H2AX protein levels (2.2-fold) in spleen at 15 mg/kg.
Increased TNF-α (1.2-fold), IL-4 (1.5-fold), and IL-1 (81-fold) in serum at 7.5 mg/kg.
Increased IL-17 (4.8-fold), TNF-α (1.52-fold), IFN-γ (4.2-fold), IL-4 (4.25-fold), IL-10 (12.3-fold), and IL-1 (427-fold) in serum at 15 mg/kg.
Dose-dependently increased mRNA levels of IL-4, IL-1, IL-10, IFN-γ, and TNF-α in splenic cytokine at 7.5 mg/kg and 15 mg/kg.
Increased p-JNK (2.5-fold), p-ERK (1.6-fold), and p-p38 (2-fold) at 7.5 mg/kg.
Increased p-JNK (2.9-fold), p-ERK (2.2-fold), and p-p38 (2.3-fold) at 15 mg/kg.
Increased p-NF-κB (1.8-fold), c-fos (1.9-fold), c-jun (2-fold), COX-2 (2.2-fold), and iNOS (2-fold) at 7.5 mg/kg.
Increased p-NF-κB (2.3-fold), c-fos (2.9-fold), c-jun (3-fold), COX-2 (2.9-fold), and iNOS (3-fold) at 15 mg/kg.

Animal Model:

Balb/c (female)^[1]
Dosage:

0.3% (sensitization); 0.15% (challenge)
Administration:

topical; once daily for 3 consecutive days (sensitization); single dose (challenge)
Result:

Increased ear swelling by 69% compared to vehicle control.
Significantly elevated ear pinna MPO activity.
Induced epidermal hyperplasia protruding into the dermis and infiltration of mixed inflammatory cells.

化学情報

CAS 番号 82-05-3
性状 Solid
分子量 230.26
分子式 C₁₇H₁₀O
Color Light yellow to yellow
SMILES

O=C1C2=C(C3=C4C1=CC=CC4=CC=C3)C=CC=C2
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

溶剤 & 溶解度

体外:

DMSO : 4 mg/mL (17.37 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.3429 mL

21.7146 mL

43.4292 mL

5 mM

0.8686 mL

4.3429 mL

8.6858 mL

10 mM

0.4343 mL

2.1715 mL

4.3429 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Tewari P, et al. Benzanthrone induced immunotoxicity via oxidative stress and inflammatory mediators in Balb/c mice. Immunobiology. 2015;220(3):369-381. [Content Brief]

[2]. Nagy E, et al. DNA adduct formation and oxidative stress from the carcinogenic urban air pollutant 3-nitrobenzanthrone and its isomer 2-nitrobenzanthrone, in vitro and in vivo. Mutagenesis. 2007;22(2):135-145. [Content Brief]

[3]. Ramdahl T. Polycyclic aromatic ketones in environmental samples. Environ Sci Technol. 1983 Nov 1;17(11):666-70. [Content Brief]

[4]. Srivastava LP, et al. Photosensitizing potential of benzanthrone. Food Chem Toxicol. 1990;28(9):653-658. [Content Brief]

[5]. Dwivedi N, et al. Skin tumorigenic potential of benzanthrone: prevention by ascorbic acid. Food Chem Toxicol. 2013;59:687-695. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.3429 mL	21.7146 mL	43.4292 mL	108.5729 mL
	5 mM	0.8686 mL	4.3429 mL	8.6858 mL	21.7146 mL
	10 mM	0.4343 mL	2.1715 mL	4.3429 mL	10.8573 mL
	15 mM	0.2895 mL	1.4476 mL	2.8953 mL	7.2382 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Benzanthrone

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

NO Synthase アイソフォーム固有の製品をすべて表示

COX アイソフォーム固有の製品をすべて表示

ERK アイソフォーム固有の製品をすべて表示

p38 MAPK アイソフォーム固有の製品をすべて表示

JNK アイソフォーム固有の製品をすべて表示

AP-1 アイソフォーム固有の製品をすべて表示

NF-κB アイソフォーム固有の製品をすべて表示

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Benzanthrone 関連分類

HY-W026930 関連分類